ARPIs for dummies! Plus the Jiffy Stent

It has becoming a familiar refrain around the world , and is certainly good news for the prostate cancer community! This week, another androgen receptor pathway inhibitor (ARPI) became reimbursed for men with hormone-sensitive metastatic prostate cancer (mHSPC) in Australia. Darolutamide is already available for men with non-metastatic castration-resistant prostate cancer, and is now also available for men with mHSPC in combination with androgen deprivation therapy and chemotherapy. Therefore we continue on our mission at GU Cast to educate ourselves about the use of ARPIs in mHSPC. And yes, even simple urologists like us can get up to speed with these drugs!

Declan and Renu are joined by fellow Urologist Associate Professor Joseph Ischia, one of our favourite prostate cancer experts. And a great podcaster himself! Check out the back catalogue of "Talking Urology". Plus what is a "jiffy stent"???

This Themed Podcast is supported by Bayer, Silver Partners of GU Cast. Also available as a classic audio podcast in all the usual places

Also available as a classic audio podcast